Energy Transfer LP has reversed its post-earnings dip with conviction — up 2.2% on the week and 5.7% over the past month to $20.78 — while the Street has responded to the Q2 print with a coordinated wave of target raises that is notable for its unanimity.
The analyst move is the standout this week. Every firm that updated its view since the Q2 results went the same direction. Truist Securities lifted its target from $23 to $25 on August 12, maintaining Buy. TD Cowen made the same move to $25 on August 10. Citigroup and Barclays both raised to $24 last week. RBC had already moved to $23 before the print. Not a single downgrade, not a single trim. The consensus mean target now sits at $24.29, roughly 17% above the current price — a gap that has widened as targets have chased the stock upward without yet catching it. Morgan Stanley remains the one measured voice, holding Equal-Weight with a $23 target, but even that is 10% above where the stock trades today. Factor scores add texture: EPS momentum over both 30-day and 90-day windows ranks strongly, EPS surprise places in the 75th percentile, and the dividend score comes in at the 92nd percentile — a reminder that income-oriented holders anchor this name.
Positioning tells a relaxed story. The post-earnings spike in the put/call ratio that defined last week's note — when the PCR hit 0.203, more than two standard deviations above its 20-day average — has fully unwound. The PCR now runs at 0.193, barely a standard deviation above its 20-day mean of 0.184, and well off the 52-week high of 0.315. Options traders are no longer reaching for downside protection at the elevated rate seen immediately after the print. The borrow market reinforces the calm: availability is running at 6,387% of short interest — roughly 64 shares available for every one borrowed — and cost to borrow, while up 10% on the week to 0.49%, remains firmly in penny-stock territory for a name this size. Short interest at 0.76% of the free float, itself down 22% in a single session on August 11, is irrelevant to any tactical thesis here.
The one piece of insider activity worth noting is modest but directionally consistent. Independent Director James Richard Perry bought just under $250,000 worth of units at $20.23 on August 7 — a small purchase but a buy at current levels rather than a legacy holding. The more consequential insider story remains founder and Executive Chairman Kelcy Warren, who added 3.35 million units across three tranches between August and November 2025 at prices around $17. At $20.78, those purchases are sitting on a 20%-plus gain. Warren holds 307 million units, nearly 9% of the company.
Among close peers, OKE gained 4.4% on the week and PR rose 4.7%, suggesting ET's 2.2% move reflects a midstream sector broadly catching a bid rather than a company-specific re-rating. EPD was the laggard, easing 0.7%. EV/EBITDA has drifted down slightly over the past month to 8.3x, and the P/E at 12.1x has compressed around 1.1 turns over 30 days — both consistent with a stock that has appreciated faster than near-term earnings estimates have moved.
The next earnings event is scheduled for November 4. Between now and then, the question is whether the Street's consensus target — still nearly $4 above the current price — acts as a gravitational pull or whether the bear case, centered on free cash flow weakness and the 19% year-over-year backlog decline flagged in the Benzinga notes, reasserts itself as a ceiling on multiple expansion.
See the live data behind this article on ORTEX.
Open ET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
